Affinity Asset Advisors LLC acquired a new position in shares of Centessa Pharmaceuticals Limited (NASDAQ:CNTA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 66,957 shares of the company’s stock, valued at approximately $1,487,000.
Several other large investors have also recently made changes to their positions in CNTA. JPMorgan Chase & Co. bought a new position in Centessa Pharmaceuticals during the second quarter valued at about $47,000. Geode Capital Management LLC bought a new position in shares of Centessa Pharmaceuticals in the second quarter worth about $211,000. State of Wisconsin Investment Board bought a new position in shares of Centessa Pharmaceuticals in the second quarter worth about $1,785,000. Monashee Investment Management LLC acquired a new stake in Centessa Pharmaceuticals during the second quarter worth about $2,887,000. Finally, Jennison Associates LLC acquired a new stake in Centessa Pharmaceuticals during the second quarter worth about $6,663,000. Institutional investors and hedge funds own 52.70% of the company’s stock.
A number of equities research analysts have weighed in on CNTA shares. Morgan Stanley started coverage on Centessa Pharmaceuticals in a report on Tuesday, June 22nd. They set an “overweight” rating and a $37.00 price objective on the stock. The Goldman Sachs Group began coverage on Centessa Pharmaceuticals in a report on Tuesday, June 22nd. They set a “buy” rating and a $42.00 price objective on the stock. Finally, Jefferies Financial Group began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company.
Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Sunday, August 15th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.06). On average, equities research analysts anticipate that Centessa Pharmaceuticals Limited will post -2.31 earnings per share for the current year.
Centessa Pharmaceuticals Profile
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency.
Recommended Story: What is a stock portfolio tracker?
Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals Limited (NASDAQ:CNTA).
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.